Gossamer Bio, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Gossamer Bio, Inc. (GOSS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are GOSS insiders buying or selling?
Gossamer Bio, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since February 2019, Trabud has recorded 60 Form 4 filings for GOSS: 25 buys ($4.5M) and 35 sells ($11.5M).
Source: SEC EDGAR Form 4
Key Statistics (February 2019 – Jun 25, 2024)
Total Form 4 filings
60
SEC EDGAR
Insider filers
13
Insider buys (25)
$4.5M
Insider sells (35)
$11.5M
Insider sentiment
Net sellingNet insider flow of $7.0M in net selling since February 2019.
Recent GOSS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 25, 2024 | Richard Aranda | Chief Medical Officer | Sale | 1.9K | $0.66 | $1.3K | SEC ↗ |
| Jun 24, 2024 | Hasnain Faheem | President & CEO | Purchase | 372.0K | $0.67 | $250.3K | SEC ↗ |
| Jun 21, 2024 | Bryan Giraudo | COO/CFO | Purchase | 100.0K | $0.59 | $59.1K | SEC ↗ |
| Jun 21, 2024 | Robert Paul Smith JR | Chief Commercial Officer | Purchase | 25.0K | $0.60 | $15.1K | SEC ↗ |
| Mar 28, 2024 | Waage Christian | EVP, Tech Ops and Admin | Sale | 6.4K | $1.16 | $7.4K | SEC ↗ |
| Mar 28, 2024 | Bryan Giraudo | COO/CFO | Sale | 6.4K | $1.16 | $7.4K | SEC ↗ |
| Mar 28, 2024 | Hasnain Faheem | President & CEO | Sale | 23.2K | $1.16 | $26.8K | SEC ↗ |
| Mar 19, 2024 | Richard Aranda | Chief Medical Officer | Sale | 4.0K | $1.33 | $5.3K | SEC ↗ |
| Mar 19, 2024 | Caryn Peterson | EVP, Regulatory Affairs | Sale | 4.0K | $1.33 | $5.3K | SEC ↗ |
| Nov 17, 2023 | Sandra Milligan | Director | Purchase | 32.0K | $0.79 | $25.2K | SEC ↗ |
| Nov 14, 2023 | Bryan Giraudo | COO/CFO | Purchase | 200.0K | $0.56 | $112.9K | SEC ↗ |
| Jun 26, 2023 | Richard Aranda | Chief Medical Officer | Sale | 1.8K | $1.29 | $2.3K | SEC ↗ |
| Apr 5, 2023 | Bryan Giraudo | COO/CFO | Purchase | 55.0K | $1.02 | $56.1K | SEC ↗ |
| Mar 22, 2023 | Waage Christian | EVP, Tech Ops and Admin | Purchase | 18.5K | $1.20 | $22.1K | SEC ↗ |
| Mar 22, 2023 | Bryan Giraudo | COO/CFO | Purchase | 50.0K | $0.97 | $48.4K | SEC ↗ |
| Mar 22, 2023 | Hasnain Faheem | President & CEO | Purchase | 878.6K | $1.14 | $1.0M | SEC ↗ |
| Mar 20, 2023 | Laura Carter | Chief Scientific Officer | Sale | 6.0K | $1.10 | $6.6K | SEC ↗ |
| Mar 20, 2023 | Richard Aranda | Chief Medical Officer | Sale | 7.6K | $1.10 | $8.3K | SEC ↗ |
| Mar 20, 2023 | Caryn Peterson | EVP, Regulatory Affairs | Sale | 7.6K | $1.10 | $8.3K | SEC ↗ |
| Oct 27, 2022 | Laura Carter | Chief Scientific Officer | Sale | 4.9K | $12.07 | $58.9K | SEC ↗ |
| Oct 25, 2022 | Caryn Peterson | EVP, Regulatory Affairs | Sale | 4.8K | $12.07 | $57.4K | SEC ↗ |
| Oct 25, 2022 | Laura Carter | Chief Scientific Officer | Sale | 4.9K | $12.07 | $58.9K | SEC ↗ |
| Oct 25, 2022 | Richard Aranda | Chief Medical Officer | Sale | 4.8K | $12.07 | $57.4K | SEC ↗ |
| Jul 15, 2022 | Laura Carter | Chief Scientific Officer | Purchase | 6.9K | $7.21 | $50.0K | SEC ↗ |
| Jul 15, 2022 | Waage Christian | EVP, Tech Ops and Admin | Purchase | 6.9K | $7.21 | $50.0K | SEC ↗ |
Showing the 25 most recent of 60 Form 4 filings for Gossamer Bio, Inc..
Most active GOSS insiders
- Bryan Giraudo13 filings
- Laura Carter8 filings
- Richard Aranda8 filings
- Waage Christian8 filings
- Hasnain Faheem7 filings
Ask anything about GOSS insider activity
Use Trabud's AI agent to query Gossamer Bio, Inc.'s Form 4 history in plain English — "Show me GOSS CEO purchases this year" or compare it against any other ticker.
Open the AI agentGOSS insider trading FAQ
Are Gossamer Bio, Inc. insiders buying or selling?
Gossamer Bio, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since February 2019, Trabud has recorded 60 Form 4 filings for GOSS: 25 buys ($4.5M) and 35 sells ($11.5M). Over the full record that is net selling of $7.0M.
How many insiders trade GOSS stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Gossamer Bio, Inc.. The most recent filing was accepted on Jun 25, 2024.
Where does Trabud get GOSS insider trading data?
All GOSS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.